The global intravenous (IV) fluid bags market is projected to grow at a compound annual growth rate (CAGR) of approximately 6 ...

First-in-class ianalumab in second-line setting led to sustained disease control ...

Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease December 9, 2025 4:15 ...

Azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia ...

The medical center earned 2026 High Performing hospital for Maternity Care recognition, the highest award a hospital can earn ...

Pfizer presents positive results from phase 3 BASIS study of Hympavzi in adults and adolescents with haemophilia A or B with inhibitors at ASH meeting: New York Tuesday, December ...

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,262% of patients treated with ...

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or ...

You can cut a few expenses without much trouble, but dropping health coverage rarely works out that way because many people ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

Postpartum depression (PPD) affects up to one in five Canadian women1; it is the most common complication2 related to childbearing and a leading cause of maternal death in Canada3Left untreated, PPD ...

When hospitals were randomly assigned to treat patients undergoing higher-risk non-cardiac surgery with tranexamic acid (TXA) ...